Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial

被引：0
|
作者：
Dreyling, Martin
Panayiotidis, Panayiotis
Egyed, Miklos
Follows, George
Mollica, Luigina
Nagler, Arnon
Ozcan, Muhit
Santoro, Armando
Ishida, Tatiane
Lu, Cindy
Hiemeyer, Florian
Garcia-Vargas, Jose
Childs, Barrett H.
Zinzani, Pier Luigi
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4053
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [21] Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
    Opat, Stephen
    Tedeschi, Alessandra
    Hu, Bei
    Linton, Kim M.
    Mckay, Pamela
    Leitch, Sophie
    Coleman, Morton
    Zinzani, Pier Luigi
    Jin, Jie
    Sun, Mingyuan
    Sobieraj-Teague, Magdalena
    Browett, Peter
    Ke, Xiaoyan
    Thieblemont, Catherine
    Ardeshna, Kirit
    Bijou, Fontanet
    Walker, Patricia
    Hawkes, Eliza A.
    Ho, Shir-Jing
    Zhou, Keshu
    Liang, Zhiyu
    Xu, Jianfeng
    Tankersley, Chris
    Delarue, Richard
    Co, Melannie
    Trotman, Judith
    BLOOD ADVANCES, 2023, 7 (22) : 6801 - 6811
  • [22] A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
    Qualls, David
    Lam, Hiu Ying
    Whiting, Karissa
    Kumar, Anita
    Matasar, Matthew
    Owens, Colette
    Nichols, Chelsea
    Espeleta, James A.
    Qiu, Annie
    Subzwari, Sarima
    Biggar, Erin
    Seshan, Venkatraman
    Salles, Gilles
    Younes, Anas
    Batlevi, Connie
    BLOOD ADVANCES, 2022, 6 (18) : 5262 - 5266
  • [23] SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)
    Tedeschi, A.
    Trotman, J.
    Zinzani, P.
    Cavallo, F.
    Marasca, R.
    Liberati, A.
    Linton, K.
    Mckay, P.
    Hu, B.
    Coleman, M.
    Ardeshna, K.
    Bijou, F.
    Marcus, R.
    Portell, C.
    Thieblemont, C.
    Bachy, E.
    Costello, R.
    Iyengar, S.
    Mocikova, H.
    Co, M.
    Li, X.
    Zhou, W.
    Cappellini, M.
    Tankersley, C.
    Huang, J.
    Opat, S.
    HAEMATOLOGICA, 2021, 106 (10) : 35 - 35
  • [24] Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial
    Opat, Stephen
    Tedeschi, Alessandra
    Linton, Kim
    McKay, Pamela
    Hu, Bei
    Chan, Henry
    Jin, Jie
    Zinzani, Pier Luigi
    Browett, Peter
    Coleman, Morton
    Sobieraj-Teague, Magdalena
    Ke, Xiaoyan
    Sun, Mingyuan
    Marcus, Robert
    Portell, Craig A.
    Zhou, Keshu
    Thieblemont, Catherine
    Co, Melannie
    Wang, Weige
    Tankersley, Chris
    Zhou, Wenxiao
    Cappellini, Massimo
    Huang, Jane
    Trotman, Judith
    BLOOD, 2020, 136
  • [25] Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients With Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open Label, Registration Directed Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 11
  • [26] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)
    Phillips, Tycel
    Avigdor, Abraham
    Gurion, Ronit
    Patti, Caterina
    Corradini, Paolo
    Tani, Monica
    Mehta, Amitkumar
    Lossos, Izidore S.
    Lossos, Izidore S.
    Zinzani, Pier Luigi Luigi
    Thieblemont, Catherine
    Jurczak, Wojciech
    Zheng, Fred
    Rappold, Erica
    Zhao, Wanying
    Johnson, Peter
    BLOOD, 2021, 138
  • [27] A PROSPECTIVE PHASE 2 TRIAL EVALUATING MONOTHERAPY WITH OFATUMUMAB FOR RELAPSED/REFRACTORY SPLENIC B-CELL MARGINAL ZONE LYMPHOMA (MORE TRIAL): SAFETY ANALYSIS RESULTS
    Scarfo', L.
    Gritti, G.
    Tedeschi, A.
    Ranghetti, P.
    Scielzo, C.
    Angelillo, P.
    Ponzoni, M.
    Ronchi, P.
    Ferreri, A.
    Ghia, P.
    HAEMATOLOGICA, 2017, 102 : 749 - 750
  • [28] Systematic Literature Review of the Clinical Efficacy and Safety of Treatments in the Relapsed/Refractory Setting for Patients with Follicular Lymphoma or Marginal Zone Lymphoma
    Monga, Neerav
    Garside, Jamie
    O'Donovan, Peter
    Quigley, Joan
    Padhiar, Amie
    Parisi, Lori
    Tapprich, Christoph
    Nastoupil, Loretta
    BLOOD, 2017, 130
  • [29] A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial
    Oh, Sung Yong
    Kim, Won Seog
    Kim, Jin Seok
    Chae, Yee Soo
    Lee, Gyeong-Won
    Eom, Hyeon Seok
    Ryoo, Hun Mo
    Lee, Suee
    Kim, Seok Jin
    Yoon, Dok Hyun
    Won, Jong Ho
    Hong, Junshik
    Park, Jinny
    Lee, Sang-Min
    Hong, Jung Yong
    Park, Eunkyung
    Kim, Hyo Jung
    Yang, Deok-Hwan
    Kim, Hyo-Jin
    Suh, Cheolwon
    LEUKEMIA & LYMPHOMA, 2016, 57 (06) : 1406 - 1412
  • [30] Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.
    Fowler, Nathan Hale
    Samaniego, Felipe
    Jurczak, Wojciech
    Lech-Maranda, Ewa
    Ghosh, Nilanjan
    Patten, Piers
    Reeves, James Andrew
    Leslie, Lori Ann
    Chavez, Julio C.
    Ghia, Paolo
    Tarella, Corrado
    Burke, John M.
    Sharman, Jeff Porter
    Kolibaba, Kathryn
    O'Connor, Owen A.
    Cheah, Chan
    Miskin, Hari P.
    Sportelli, Peter
    Weiss, Michael S.
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345